12th February 2020
What happens after Brexit for Pharmacovigilance and Regulatory?

What happens after Brexit for Pharmacovigilance and Regulatory?

7th February 2020
Pharmacovigilance (QPPV) provision post-Brexit

Pharmacovigilance (QPPV) provision post-Brexit

There has been and still is a huge amount of confusion regarding the requirements for establishing a UK QPPV following the UK’s exit from Europe on […]
15th January 2020

Is your pharmaceutical company Brexit ready?

Pure Drug Safety is ready to help you with your post Brexit pharmacovigilance and regulatory requirements – deal or no deal. Just call us now for […]
22nd July 2019

Yellow fever vaccine

Yellow fever vaccine – following two fatalities – the vaccine must not be given to patients that present with a history of thymus dysfunction, or is […]
4th April 2019

Breast Implants Safety Concerns – the Importance of Post-Marketing Surveillance

Recently, (24 March 2019), the FDA have started to scrutinise the safety of breast implants, which brings into focus the importance of post-marketing surveillance in patient […]
4th April 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019

EU referral procedures for safety reasons: Just started – review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine. The review to examine existing […]
21st March 2019

The World Tuberculosis Day – 24 March

TB is the world’s deadliest infectious killer. The disease is preventable and curable. Globally the TB mortality rate has reduced by 42% since 2000 (saving an […]